Final survival outcomes and immune biomarker analysis of a randomized, open-label, phase I/II study combining oncolytic adenovirus ONCOS-102 with pemetrexed/cisplatin (P/C) in patients with ...

Pleural mesothelioma (PM) is mainly caused by asbestos exposure and characterized by poor prognosis and limited therapeutic options. A recent research study identified the oncoprotein YB-1 as an ...

Mesothelioma is an aggressive tumor with a poor prognosis. Histological diagnosis of mesothelioma using limited tissue samples can be challenging. Carbonic anhydrase IX (CAIX) is a transmembrane ...

Nobody likes to talk or think about cancer, but it’s a serious disease that we should all aim to understand a little better. Better understanding the signs and symptoms of cancer, as well as how to ...

Please provide your email address to receive an email when new articles are posted on . Access to care varied significantly among patients with stage I to stage III malignant pleural mesothelioma, ...

Over the past 15 or 20 years, a rare form of cancer known as mesothelioma has become increasingly common – affecting as many as 3,000 Americans each year. Additionally, roughly 2,500 ...

Patients with malignant pleural mesothelioma are diagnosed at advanced stages and have limited treatment options. Patients with coexpression of ERCC1 and RPM1 in tumor tissues exhibited significantly ...

To date, there is no standard therapy for malignant pleural mesothelioma. Historically, surgery is potentially beneficial in patients with low-volume disease, but in patients for whom surgery is not ...

A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18fdg-PET. Background: Available prognostic scores in malignant pleural mesothelioma (MPM) are based on ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to chemotherapy significantly extended OS as first-line therapy for advanced ...

Nearly one in five patients with malignant pleural mesothelioma (MPM) at a Barcelona hospital contracted COVID-19 during the pandemic. In addition, those patients suffered a 75% mortality rate, ...